for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vaccitech, startup behind AstraZeneca's COVID-19 vaccine, targets $613 mln valuation in U.S. IPO

April 13 (Reuters) - Biotech startup Vaccitech, which owns the technology behind the COVID-19 vaccine developed by AstraZeneca Plc jointly with the Oxford University, said on Monday it was aiming for a valuation of up to $613 million in its U.S. initial public offering.

Reporting by Niket Nishant in Bengaluru

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up